 |
| Date | Title | | | 02/06/12 | Ardea Biosciences Announces Exercise in Full of Over-Allotment Option and Completion of Public Offering of Common Stock| SAN DIEGO, CA, Feb 06, 2012 (MARKETWIRE via COMTEX) -- Ardea Biosciences, Inc. (NASDAQ: RDEA) today announced the completion of an underwritten public offering of 9,775,000 shares of its common stock, including 1,275,000 shares sold pursuant to the full exercise of an over-allotment option previously granted to the underwriters. All of the shares were offered by Ardea at a price to the public of $17.00 per share. The gross proceeds to Ardea from this offering were approximately $166.2 million, b... |
|  | | 02/01/12 | Ardea Biosciences Prices Public Offering of Common Stock| SAN DIEGO, CA, Feb 01, 2012 (MARKETWIRE via COMTEX) -- Ardea Biosciences, Inc. (NASDAQ: RDEA) today announced the pricing of an underwritten public offering of 8,500,000 shares of its common stock, offered at a price to the public of $17.00 per share. The gross proceeds to Ardea from this offering are expected to be $144.5 million, before deducting underwriting discounts and commissions and other estimated offering expenses payable by Ardea. Ardea has granted the underwriters a 30-day option to ... |
| | | 01/31/12 | Ardea Biosciences Announces Proposed Public Offering of Common Stock| SAN DIEGO, CA, Jan 31, 2012 (MARKETWIRE via COMTEX) -- Ardea Biosciences, Inc. (NASDAQ: RDEA) today announced that it intends to offer and sell, subject to market and other conditions, shares of its common stock in an underwritten public offering. There can be no assurance as to whether or when the offering may be completed, or as to the actual size or terms of the offering.
Jefferies & Company, Inc. is acting as sole book-running manager for the offering. Cowen and Company, LLC, Lazard Ca... |
| | | 12/19/11 | Ardea Biosciences Initiates Phase 3 Clinical Development Program for Lesinurad| SAN DIEGO, CA, Dec 19, 2011 (MARKETWIRE via COMTEX) --Ardea Biosciences, Inc. (NASDAQ: RDEA) today announced that it has initiated the first of four planned Phase 3 clinical trials in its development program for lesinurad, the Company's lead product candidate for the chronic treatment of gout. The lesinurad Phase 3 development program is expected to involve approximately 2,000 gout patients at sites around the world. The remaining Phase 3 studies in the program are expected to begin shortly.
"... |
| |
|
|
| There are currently no events scheduled. |
Replication or redistribution of EDGAR Online, Inc. content is expressly prohibited without the prior written consent of EDGAR Online, Inc. EDGAR Online, Inc. shall not be liable for any errors or delays in the content, or for any actions taken in reliance thereon. |
|
